Literature DB >> 30267008

Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues.

Bola S Hanna1, Philipp M Roessner2, Haniyeh Yazdanparast2, Dolors Colomer3, Elias Campo3, Sabrina Kugler4, Deyan Yosifov4, Stephan Stilgenbauer4, Manfred Schmidt5, Richard Gabriel5, Peter Lichter2, Martina Seiffert6.   

Abstract

Chronic lymphocytic leukemia (CLL) is associated with substantial alterations in T-cell composition and function. However, the role of T-cells in CLL remains largely controversial. Here, we utilized the Eµ-TCL1 mouse model of CLL as well as blood and lymph node samples of CLL patients to investigate the existence of anti-tumoral immune responses in CLL, and to characterize involved immune cell populations. Thereby, we identified an oligoclonal CD8+ effector T-cell population that expands along with CLL progression and controls disease development. We further show that a higher percentage of CD8+ effector T-cells produces IFNγ, and demonstrate that neutralization of IFNγ results in faster CLL progression in mice. Phenotypical and functional analyses of expanded CD8+ effector T-cells show significant differences in disease-affected tissues in mice, with cells in secondary lymphoid organs harboring hallmarks of activation-induced T-cell exhaustion. Notably, we further describe a respective population of exhausted CD8+ T-cells that specifically accumulate in lymph nodes, but not in peripheral blood of CLL patients. Collectively, these data emphasize the non-redundant role of CD8+ T-cells in suppressing CLL progression and highlight their dysfunction that can be exploited as target of immunotherapy in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30267008     DOI: 10.1038/s41375-018-0250-6

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  47 in total

1.  Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.

Authors:  R R Furman; Z Asgary; J O Mascarenhas; H C Liou; E J Schattner
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

Review 2.  Perturbation of the normal immune system in patients with CLL.

Authors:  Francesco Forconi; Paul Moss
Journal:  Blood       Date:  2015-06-17       Impact factor: 22.113

3.  Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.

Authors:  Simone Bürgler; Aleix Gimeno; Anna Parente-Ribes; Dong Wang; Audun Os; Stephen Devereux; Peter Jebsen; Bjarne Bogen; Geir E Tjønnfjord; Ludvig A Munthe
Journal:  J Immunol       Date:  2014-12-10       Impact factor: 5.422

4.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

Authors:  L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia.

Authors:  Wendelina J M Mackus; Florine N J Frakking; Annette Grummels; Laila E Gamadia; Godelieve J De Bree; Dorte Hamann; Rene A W Van Lier; Marinus H J Van Oers
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

6.  Clinical significance of T-cells in chronic lymphocytic leukaemia.

Authors:  D Catovsky; E Miliani; A Okos; D A Galton
Journal:  Lancet       Date:  1974-09-28       Impact factor: 79.321

7.  Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Authors:  J Piñón Hofbauer; C Heyder; U Denk; T Kocher; C Holler; D Trapin; D Asslaber; I Tinhofer; R Greil; A Egle
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells.

Authors:  Audun Os; Simone Bürgler; Anna Parente Ribes; Ane Funderud; Dong Wang; Keith M Thompson; Geir E Tjønnfjord; Bjarne Bogen; Ludvig A Munthe
Journal:  Cell Rep       Date:  2013-08-08       Impact factor: 9.423

10.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

View more
  26 in total

1.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

2.  Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Maria Joao Baptista; Sivasubramanian Baskar; Erika M Gaglione; Keyvan Keyvanfar; Inhye E Ahn; Adrian Wiestner; Clare Sun
Journal:  Clin Cancer Res       Date:  2021-04-19       Impact factor: 13.801

3.  Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia.

Authors:  Lena Schulze-Edinghausen; Claudia Dürr; Selcen Öztürk; Manuela Zucknick; Axel Benner; Verena Kalter; Sibylle Ohl; Viola Close; Patrick Wuchter; Stephan Stilgenbauer; Peter Lichter; Martina Seiffert
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

Review 4.  Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?

Authors:  Ebru Aydin; Sebastian Faehling; Mariam Saleh; Laura Llaó Cid; Martina Seiffert; Philipp M Roessner
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

Review 5.  T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.

Authors:  Elisavet Vlachonikola; Kostas Stamatopoulos; Anastasia Chatzidimitriou
Journal:  Front Immunol       Date:  2021-01-20       Impact factor: 7.561

6.  Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.

Authors:  Neus Giménez; Ralph Schulz; Laia Rosich; Martina Seiffert; Dolors Colomer; Morihiro Higashi; Marta Aymerich; Neus Villamor; Julio Delgado; Manel Juan; Mònica López-Guerra; Elias Campo
Journal:  Leukemia       Date:  2019-06-13       Impact factor: 11.528

7.  CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.

Authors:  Matteo Grioni; Arianna Brevi; Elena Cattaneo; Alessandra Rovida; Jessica Bordini; Maria Teresa Sabrina Bertilaccio; Maurilio Ponzoni; Giulia Casorati; Paolo Dellabona; Paolo Ghia; Matteo Bellone; Arianna Calcinotto
Journal:  Blood Adv       Date:  2021-07-27

8.  Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.

Authors:  Justyna A Wierzbinska; Reka Toth; Naveed Ishaque; Karsten Rippe; Jan-Philipp Mallm; Lara C Klett; Daniel Mertens; Thorsten Zenz; Thomas Hielscher; Marc Seifert; Ralf Küppers; Yassen Assenov; Pavlo Lutsik; Stephan Stilgenbauer; Philipp M Roessner; Martina Seiffert; John Byrd; Christopher C Oakes; Christoph Plass; Daniel B Lipka
Journal:  Genome Med       Date:  2020-03-18       Impact factor: 11.117

Review 9.  Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.

Authors:  Maissa Mhibik; Adrian Wiestner; Clare Sun
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

Review 10.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-09-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.